Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

982 recalls · Class II, newest first

Class II · Moderate risk

Methyl-Cobalamin injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1162-2018
Class II · Moderate risk

Methyl-Cobalamin injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1161-2018
Class II · Moderate risk

Methyl-Cobalamin injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1160-2018
Class II · Moderate risk

Glutathione injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1159-2018
Class II · Moderate risk

Dexpanthenol injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1158-2018
Class II · Moderate risk

Calcium Gluconate injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1157-2018
Class II · Moderate risk

CoEnzyme-Q10 injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1156-2018
Class II · Moderate risk

Thyroid Powder 25kg/drum

CGMP Deviations: Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.

Terminated cGMP deviation Sichuan Friendly Pharmaceutical Co.,Ltd. NDC 7807-0170-11 D-0006-2019
Class II · Moderate risk

Montelukast Sodium Tablets

Discoloration: A complaint was received from a pharmacist for the presence of blue specks on tablets.

Terminated Failed specification Hetero Labs Limited Unit V NDC 31722-726-30 D-1213-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1145-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1144-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1143-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1142-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1141-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1136-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1135-2018

Recalls by year